Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis

Table 1 Model resource inputs for medication and services of healthcare professionals in Ontario and Quebec

Resource	Ontario						Quebec
	Ragweed SLIT-tablet	Preseasonal ragweed SCIT	Annual SCIT			MRPATA	Ragweed SLIT-tablet	Preseasonal ragweed SCIT	Annual SCIT			MRPATA
	Years 1, 2, and 3 each	Years 1, 2, and 3 each	Year 1	Year 2	Year 3	Years 1, 2, and 3 each	Years 1, 2, and 3 each	Years 1, 2, and 3 each	Year 1	Year 2	Year 3	Years 1, 2, and 3 each
Number of tablets	180	0	0	0	0	0	180	0	0	0	0	0
Number of treatment sets or maintenance vials	0	1	2	2	2	0	0	1	2	2	2	0
Number of 10 mL vials	0	0	0	0	0	1	0	0	0	0	0	1
Number of claims	6	1	2	2	2	1	6	1	2	2	2	1
Number of start-up visits	1	0	0	0	0	0	1	0	0	0	0	0
GP (5%)	0.05	0	0	0	0	0	0.05	0	0	0	0	0
Specialist (95%)	0.95	0	0	0	0	0	0.95	0	0	0	0	0
Number of follow-up visit	1	0	0	0	0	0	1	0	0	0	0	0
GP (10%)	0.1	0	0	0	0	0	0.1	0	0	0	0	0
Specialist (90%)	0.9	0	0	0	0	0	0.9	0	0	0	0	0
Number of titration visits	0	11	25	0	0	4	0	11	25	0	0	4
GP (10% SCIT, 80% MRPATA)	0	1.1	2.5	0	0	3.2	0	1.1	2.5	0	0	3.2
Specialist (90% SCIT, 20% MRPATA)	0	9.9	22.5	0	0	0.8	0	9.9	22.5	0	0	0.8
Number of maintenance visits	0	0	6.75	13	13	0	0	0	6.75	13	13	0
GP (95%)	0	0	6.41	12.35	12.35	0	0	0	6.41	12.35	12.35	0
Specialist (5%)	0	0	0.34	0.65	0.65	0	0	0	0.34	0.65	0.65	0
Number of consultation visits, with injection	0	11	31.75	13	13	4	0	11	31.75	13	13	4
GP (10% SCIT, 80% MRPATA)	0	1.1	8.91	12.35	12.35	0.8	0	1.1	8.91	12.35	12.35	0.8
Specialist (90% SCIT, 20% MRPATA)	0	9.9	22.84	0.65	0.65	3.2	0	9.9	22.84	0.65	0.65	3.2
Number of consultation visits, no injection	0	1	1	1	1	1	0	1	1	1	1	1
GP (20%)	0	0.2	0.2	0.2	0.2	0.2	0	0.2	0.2	0.2	0.2	0.2
Specialist (80%)	0	0.8	0.8	0.8	0.8	0.8	0	0.8	0.8	0.8	0.8	0.8
Nurse: time worked for injections, h	0	5.50	15.88	6.50	6.50	2.00	0	0^a	0^a	0^a	0^a	0^a

GP general practitioner, MRPATA modified ragweed pollen allergen tyrosine adsorbate, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy
^aNo nurse observation time was included because it is not covered by the Régie de l’assurance maladie du Québec

ISSN: 1710-1492